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Purpose: To evaluate the clinicopathological characteristics and prognosis of local-
ized resectable genitourinary sarcomas in adults. Materials and Methods: Be-
tween September, 1996 and November, 2008, 18 consecutive cases of adults (12 
men and 6 women; median age 48.8 years) who were treated for primary genitouri-
nary sarcomas were identified. The following variables were analyzed: patient age, 
gender, body mass index, American Society of Anesthesiologists (ASA) score, pri-
mary organ, tumor histology, size, necrosis, Fédération Nationale des Centres de 
Lutte Contre le Cancer (FNCLCC) grade, and surgical margin positivity. Recur-
rence-free survival and disease-specific survival were the study end-points. Re-
sults: The most common presenting symptom was a palpable mass (six cases, 
33.3%), the most common site was the kidney (six cases, 33.3%), and the most 
common histological subtype was leiomyosarcoma (eight patients, 44.4%). Com-
plete resection with negative surgical margins was achieved in 13 patients (72.2%). 
The median follow-up period was 49.9 months (range 6.4 to 147.6). The recur-
rence-free survival rates at 1, 3, and 5 years were 81.6%, 66.5%, and 66.5%, re-
spectively. Recurrence-free survival only associated significantly with ASA score 
(p=0.018). The disease-specific survival rate at 1, 3, and 5 years was 88.9%, 76.2%, 
and 67.7%, respectively. Disease-specific survival was associated significantly only 
with FNCLCC grade (p=0.042). Conclusion: Although genitourinary sarcomas in 
adults are a rare group of tumors with a poor prognosis, some patients may have a 
favorable prognosis. Our findings suggest that FNCLCC grade is the most impor-
tant prognostic factor for these patients.
Key Words:    Urogenital neoplasms, sarcoma, genitourinary tract, survival, prog-
nosis
INTRODUCTION
Sarcomas are a heterogeneous group of rare tumors that arise predominantly from 
the embryonic mesoderm and account for about 1% of all malignant tumors.1 Soft 
tissue sarcoma of the genitourinary tract are rare, accounting for only 2.1% of soft 
tissue sarcomas and 1% to 2% of all malignant genitourinary tumors.2,3 Due to Sung Yong Cho, et al.
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come. Patients with distant metastases were excluded from 
the analysis. The patient evaluation included a complete 
medical history, physical examination, laboratory investiga-
tions, and radiologic imaging data (chest X-ray, computer-
ized tomography and/or magnetic resonance imaging, and 
bone scans). Preoperative staging revealed that none of the 
patients had metastatic disease at presentation. Our series 
only included sarcomas of the genitourinary tract such as 
kidney, ureter, bladder, prostate, urethra, and paratesticular 
region. Retroperitoneal sarcomas involving the genitourinary 
organs were excluded from the analysis. The genitourinary 
sarcomas were characterized on the basis of positive and 
negative staining for specific immunohistochemical markers 
(Table 1). All cases were classified according to the French 
Federation of Cancer Center System Grading Scheme for 
Adult Sarcoma. In the French System, three parameters are 
scored individually, namely, tumor differentiation, mitotic ac-
tivity, and the degree of tumor necrosis. These individual 
scores are summed up to yield a final score (I, II, or III) that 
indicates the grade of the sarcoma.6  
their rarity, there are very few studies on genitourinary sar-
comas in the literature,4,5 and little is known about their nat-
ural history and prognosis. In the present study, we ana-
lyzed the clinicopathological characteristics and prognosis 
of 18 cases of localized resectable genitourinary sarcomas 
in adults that were collected in a single institution. To the 
best of our knowledge, this is the first study of genitouri-
nary sarcomas in adults in an Asian population.
  
MATERIALS AND METHODS
　　　
Patients
Approval to perform this study was obtained from the insti-
tutional review board. Between September, 1996 and No-
vember, 2008, consecutive adult patients who were treated 
for primary genitourinary sarcomas at our hospital were 
identified through a database search. Their medical records 
were thoroughly reviewed for pertinent information regard-
ing the presentation, tumor characteristics, therapy, and out-
Table 1. Immunohistochemical Staining Patterns of Genitourinary Sarcoma Subtypes
Pt. no. Histologic subtype Positive Negative
  1 Carcinosarcoma Cytokeratin (weakly), vimentin -
  2  Leiomyosarcoma Desmin, smooth muscle actin, vimentin Alpha1-antitrypsin, S-100
  3 Rhbdomyosarcoma Myoglobulin, vimentin (weakly) Desmin, smooth muscle actin, S-100
  4 Leiomyosarcoma Smooth muscle actin, vimentin  Cytokeratin 
  5  Leiomyosarcoma Desmin, smooth muscle actin S-100
  6 Leiomyosarcoma Desmin, smooth muscle actin, vimentin  Cytokeratin, myoglobulin, S-100
  7 Leiomyosarcoma Desmin, smooth muscle actin Myoglobulin 
  8 Rhbdomyosarcoma - -
  9 Liposarcoma - -
10 Leiomyosarcoma
Desmin (a few), ki-67 (2%), smooth muscle actin, 
  vimentin
Beta-catenin, cytokeratin, S-100
11 MFH Desmin (focal), smooth muscle actin (focal), vimentin  CD34, CD68, S-100 
12 Synovial sarcoma
Bcl-2 (weakly), cytokeratin (epithelail component), 
  desmin (weakly), epithelial membrane antigen 
  (epithelial component), S-100 (a few)
PSA, smooth muscle actin
13 Liposarcoma Desmin, smooth muscle actin HMB45, S-100
14 Leiomyosarcoma Smooth muscle actin  -
15 Ewing’s sarcoma/PNET CD99 CD56, cytokeratin, vimentin
16 MFH CD68 (focal), desmin (a few), ki67 (5%), vimentin
Cytokeratin, epithelial membrane 
  antigen, myogenin, myoglobulin, 
  smooth muscle actin, S-100
17 Synovial sarcoma
Bcl-2, CD99 (focal), epithelial membrane antigen, 
  ki-67 (focal), vimentin
Cytokeratin, smooth muscle actin, 
  S-100
18 Leiomyosarcoma
c-kit (focal), HMB45 (focal), ki-67 (10%), p53 (<25%), 
  smooth muscle actin, S-100 (focal), vimentin
CD31, CD34, desmin, myogenin
Pt. no., patient number; PNET, primitive neuroectodermal tumor; MFH, malignant fibrous histiocytoma.Outcomes of Adult Genitourinary Sarcoma
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Statistical analysis
The date of surgery served as the start of observation, and 
recurrence-free survival and disease-specific survival were 
the study end-points. Recurrence was defined as recurrent 
disease at a local or distant site. Death caused by disease 
was the only end-points for disease-specific survival. The 
actuarial probability of these end-points was modeled by 
the Kaplan-Meier method. Univariate analysis of variables 
associated with survival end points was performed by using 
the log-rank test. The variables that were analyzed were pa-
tient age, gender, body mass index, American Society of 
Anesthesiologists (ASA) score, primary organ, tumor his-
tology, size, necrosis, Fédération Nationale des Centres de 
Lutte Contre le Cancer (FNCLCC) grade, and surgical mar-
gin positivity. With regard to the continuous variables, the 
patients were stratified into two groups: for age, two groups 
were ≤50 years and >50 years; for body mass index, they 
were ≤23.0 kg/m2 and >23.0 kg/m2; for ASA score, they 
were 1 or >1; for tumor size, they were ≤5 cm and >5 cm; 
and for FNCLCC grade, they were 1 or >1. Tumor location 
was categorized as kidney and others, and histologic sub-
type was categorized as leiomyosarcoma and others. Due to 
the small sample size, multivariate models were not appro-
priate.7 For all statistical analyses, p<0.05 was considered 
significant. All statistical tests were performed by the Sci-
entific Package for Social Sciences software.  
RESULTS
 
The characteristics of the 18 patients are summarized in Ta-
ble 2. There were 12 males and six females. The mean and 
median ages at presentation were 47.8 and 48.8 years, re-
spectively. The most common presenting symptom was a 
palpable mass (33.3%), and the most common site was kid-
ney (six cases, 33.3%), followed by bladder (three, 16.7%), 
prostate (three, 16.7%), paratesticular region (three, 16.7%), 
renal pelvis/ureter (two, 11.1%) and urethra (one, 5.6%). 
The most common histological subtype was leiomyosarco-
ma (eight patients, 44.4%), followed by liposarcoma, rhab-
domyosarcoma, synovial sarcoma, malignant fibrous histio-
cytoma (MFH) [two patients (11.1%) each], and others (two 
patients, 11.1%). Complete resection with negative surgical 
margins was achieved in 13 patients (72.2%). 
The outcome of the patients with genitourinary sarcoma 
is shown in Table 3. Of the 18 patients, none underwent 
neoadjuvant treatment. The median follow-up period for 
Table 2. Patient Characteristics
Variables
Gender 
    Male 12 (66.7%)
    Female   6 (33.3%)
Age (yrs)
    Median 48.8
    Range 19.0-68.4
Body mass index (kg/m
2)
    Median 22.8
    Range 16.9-30.7
American Society of Anesthesiologists score
    1 11 (61.1%)
    2   6 (33.3%)
    3   1 (5.6%)
Symptoms
    Palpable mass   6 (33.3%)
    Abdominal/flank pain   2 (11.1%)
    Gross hematuria   4 (22.2%)
    Voiding difficulty   3 (16.7%)
    Dyspareunia   1 (5.6%)
    None    2 (11.1%)
Tumor location
    Kidney   6 (33.3%)
    Renal pelvis/ureter   2 (11.1%)
    Bladder   3 (16.7%)
    Prostate   3 (16.7%)
    Urethra   1 (5.6%)
    Paratesticular    3 (16.7%)
Histologic subtype
    Leiomyosarcoma   8 (44.4%)
    Liposarcoma   2 (11.1%)
    Rhabdomyosarcoma   2 (11.1%)
    Synovial sarcoma   2 (11.1%)
    Malignant fibrous histiocytoma   2 (11.1%)
    Ewing’s sarcoma/PENT   1 (5.6%)
    Carcinosarcoma   1 (5.6%)
Tumor size (cm) 
    Median   6.8
    Range   1.5-19.0
FNCLCC grade
    1   7 (38.9%)
    2   4 (22.2%)
    3   7 (38.9%)
Tumor necrosis
    No 10 (55.6%)
    Yes   8 (44.4%)
Margin status
    Negative 13 (72.2%)
    Positive   5 (27.8%)
PNET, primitive neuroectodermal tumor; FNCLCC, Fédération Nationale 
des Centres de Lutte Contre le Cancer.Sung Yong Cho, et al.
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the 18 patients was 49.9 months (mean 
62.9; range 6.4 to 147.6). Of all patients, 
six patients (33.3%) developed recurrent 
disease at a median time to surgery of 17.9 
months (mean 28.6; range 4.4 to 89.0). The 
recurrence-free survival rate at 1, 3, and 5 
years was 81.6%, 66.5%, and 66.5%, re-
spectively. On univariate analysis, recur-
rence-free survival significantly associated 
only with ASA score (Fig. 1A). At a medi-
an follow-up period of 4.0 years, ten pa-
tients (55.6%) had no evidence of disease, 
two (11.1%) had disease, five (27.8%) had 
died of the disease, and one (5.6%) had 
died of other cause. The disease-specific 
survival rate at 1, 3, and 5 years was 
88.9%, 76.2%, and 67.7%, respectively. On 
univariate analysis, disease-specific surviv-
al was significantly associated only with 
FNCLCC grade. Fig. 1B depicts the dis-
ease-specific survival curve of the 18 pa-
tients according to FNCLCC grade. 
DISCUSSION
Sarcomas of the kidney
Two of our patients had leiomyosarcomas 
of the kidney. Leiomyosarcoma accounts 
for 50-60% of all renal sarcomas, there-
fore, it is the most common histologic 
subtype.8 Renal leiomyosarcoma has a 
very poor prognosis, with most patients 
dying within two years,9,10 but radical sur-
gery seems to offer the best chance of 
cure. The role of adjuvant chemotherapy 
and/or radiotherapy remains debatable due 
to the paucity of data on the treatment of 
this rare renal neoplasms. While local re-
currence is common, low-grade leiomyo-
sarcoma tends to pursue a more indolent 
course. Of our cases, two patients had a 
low-grade leiomyosarcomas and no evi-
dence of local recurrence or distant metas-
tasis was noted during 57.2 and 147.6 
months of follow-up. 
One of our patients had primary renal 
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regimen. At the 9-year follow-up, he is still alive without 
disease recurrence.  
Leiomyosarcoma of the ureter
One of our patients had leiomyosarcoma of the ureter. A re-
cent literature review found less than 20 cases of primary 
leiomyosarcoma of the ureter.14 Generally, as indicated by 
the short survival of the reported cases, the prognosis of this 
disease is unfavorable. Our patient was treated surgically 
by ureterectomy and the cutting margin of the ureter was 
negative. Adjuvant radiation therapy was given after sur-
gery and the patient remains free of the disease 108 months 
after surgery. Although adjuvant chemotherapy has not yet 
been proven to be effective and remains to be tested, wide 
local excision and radiation therapy could be the treatment 
of choice for leiomyosarcoma of the ureter.14 
Leiomyosarcoma of the urinary bladder 
Our series contained three cases of leiomyosarcoma of the 
urinary bladder. To date, over 200 cases of bladder sarco-
mas have been reported. Of these, 50% were leiomyosarco-
mas, 20% were rhabdomyosarcomas, and the remainder 
consisted of other histologies, namely carcinosarcomas, an-
giosarcomas and osteosarcomas.15 Spiess, et al.16 did not 
detect any differences in disease-specific and overall sur-
vival durations between patients with bladder leiomyosar-
coma and other sarcoma subtypes. Analysis of M.D. Ander-
son Cancer Center data showed that bladder sarcoma is 
associated with a 5-year disease-specific survival rate of 
59.0-62.0%.16,17 Thus, bladder leiomyosarcoma is thought 
to have a poor prognosis. However, Rosso, et al.18 reviewed 
their experiences at the Memorial Sloan-Kettering Cancer 
synovial sarcoma, which is an extremely rare neoplasm that 
was discovered only relatively recently. Regardless of the 
treatment, the prognosis of renal synovial sarcoma remains 
poor. Indded, our case expired 6.4 months after radical ne-
phrectomy.
Our another patient had renal carcinosarcomam which 
tended to be large and bulky due to its rapid growth and 
wide infiltration. It is known to progress rapidly and is as-
sociated with a poor prognosis. Kuroda, et al.11 have report-
ed the case pf a patient with renal carcinosarcoma who died 
of systemic metastases 5 months after radical nephrectomy. 
The tumor of our patient also recurred 4.4 months after rad-
ical nephrectomy; the patient remains alive with disease 8.9 
months after surgery. 
The remaining two patients of our series with kidney sar-
comas had Ewing’s sarcoma/primitive neuroectodermal tu-
mor (PNET) and MFH, respectively. Both are also character-
ized by an aggressive clinical course and a poor prognosis. 
Indeed, both of our patients had a poor outcome: one was 
dead from the disease and the other is alive with the disease.
Rhabdomyosarcoma of the renal pelvis
One of our patients had rhabdomyosarcoma of the renal pel-
vis. This is a very rare renal pelvis neoplasm, especially in 
adults, with only two cases of renal pelvis rhabdomyosarco-
ma in adults being reported to date.12,13 With regard to patho-
logical subclassification, these tumors were of embyronal 
and pleomorphic type, respectively. Our case was found to 
have pleomorphic rhabdomyosarcoma. He was subjected to 
radical nephrectomy, after which he received 18 cycles of 
post-operative chemotherapy with the vincristine, adriamy-
cin, cyclophosphamide (VAC)/ifostamide and etoposide (IE) 
Fig. 1. (A) Kaplan-Meier survival analysis of the recurrence-free survival of 18 genitourinary sarcomas on the basis of the American Society of Anesthesiologists 
score. (B) Kaplan-Meier survival analysis of the disease-specific survival of 18 genitourinary sarcomas on the basis of the Fédération Nationale des Centres de 
Lutte Contre le Cancer grade. ASA, American Society of Anesthesiologists; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer.
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patient was surgically treated (wide local excision), and un-
derwent adjuvant radiotherapy, and shows no sign of recur-
rence after more than 10 years of follow-up. 
Paratesticular sarcomas
The remaining three patients in our series had paratesticular 
sarcomas, which can arise from the epididymis, the mesen-
chymal layers surrounding the testis and its true appendag-
es, and the spermatic cord. Two of our patients were diag-
nosed with liposarcoma and one with leiomyosarcoma, and 
all sarcomas were well differentiated. Unlike paratesticular 
rhabdomyosarcoma, there are very few reports of parates-
ticular leiomyosarcomas and liposarcomas.21,22 Fisher, et 
al.21 have shown that treatment by radical orchiectomy may 
prevent patients with low grade paratesticular leiomyosar-
coma from developing recurrences and metastasrs. Mont-
gomery and Fisher22 also reported that paratesticular lipo-
sarcomas are often well differentiated and have a prolonged 
clinical course. Our three patients were treated by radical 
orchiectomy with high ligation of the spermatic cord. Ret-
roperitoneal lymphadenectomy or chemotherapy was not 
performed because retroperitoneal lymphadenectomy did 
not seem to offer any additional therapeutic benefit and the 
role of chemotherapy is not well defined. The tumors were 
incompletely excised in two cases, but all patients had no 
evidence of disease at a follow-up period of 33.1, 101.1 and 
106.6 months, respectively. 
Survival rates associated with genitourinary sarcoma
The disease-specific survival rate of patients with genitouri-
nary sarcoma is worse than that for patients with soft tissue 
sarcoma at all sites.23 The relatively poor prognosis of geni-
tourinary sarcoma may be explained by the higher propor-
tion of high grade tumors, the higher proportion of patients 
who present with metastatic disease, a larger tumor size, 
and the anatomical site. In addition, the rarity and heteroge-
neity of genitourinary sarcomas mean wide differences in 
the outcomes of the various subgroups. In our series, the 
disease-specific survival rates at 1-, 3-, and 5-years were 
88.9%, 76.2%, and 67.7%, respectively. Mondaini, et al.4 
reported 1-, 3-, and 5-year overall survival rates of 85.9%, 
62.0% and 48.8%, respectively, whereas Dotan, et al.5 re-
ported a 5-year survival rate of 69% in patients without 
clinical evidence of metastasis at diagnosis, which is simi-
lar to our findings. 
We found in the present study that only the ASA score at 
presentation was associated with recurrence-free survival 
Center, stating that some patients with bladder leiomyosar-
coma are able to achieve long-term survival. They also re-
ported a remarkable 5-year disease-specific survival rate of 
84.0%. In the present study, all three patients with bladder 
leiomyosarcoma underwent partial cystectomy as the only 
mode of treatment. One patient continues to do well with-
out evidence of disease recurrence, but two patients died of 
the disease 29.6 months and 27.9 months after surgery, re-
spectively. Interestingly, the patient with no evidence of 
disease had positive margins after surgery, and adjuvant 
treatment was not advocated. However, as shown for other 
soft tissue sarcomas, patients with positive surgical margins 
can be candidates for adjuvant radiotherapy.19 Thus, our ex-
periences suggest that leiomyosarcoma of the bladder should 
be treated by radical cystectomy if surgical resection is pos-
sible, while partial cystectomy should be considered as a 
palliative treatment, even when free margins are achieved.
Sarcomas of the prostate
Three of our patients had sarcomas of the prostate. The rare 
occurrence of prostate sarcomas in adults means that the 
survival rates associated with this disease can be inferred 
only from anecdotal experiences; its rarity has also limited 
the development of effective treatment strategies. Surgery 
has been the mainstay of treatment and usually involves 
cystoprostatectomy or total pelvic exenteration. Historical-
ly, the long-term survival rates for adult patients with pros-
tate sarcoma are poor. However, Sexton, et al.20 suggest that 
a combined multimodality approach, where surgery is the 
mainstay of treatment and usually involves cystoprostatec-
tomy, may result in improved survival rates. The 1-, 3- and 
5-year acturarial survival rates of their 21 patients were 81%, 
43% and 38%, respectively. In our series, one patient, who 
had rhabdomyosarcoma, received adjuvant radiotherapy 
and multiagent chemotherapy, however, died of metastatic 
sarcoma at 7.4 months. The second patient, who had MFH, 
was treated with cystoprostatectomy, but did not receive 
adjuvant treatment, and showed no evidence of disease 
99.2 months later. The third patient, who had synovial sar-
coma, received adjuvant radiotherapy and multiagent che-
motherapy, but died of metastatic prostate sarcoma 56.1 
months after surgery.  
Leiomyosarcoma of the urethra
One patient in our series had leiomyosarcoma of the ure-
thra. To our best knowledge, primary leiomyosarcoma of 
the urethra in women has not been reported previously. Our Outcomes of Adult Genitourinary Sarcoma
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ington DC: Armed Forces Institute of Pathology 1994. p.158-61.
9. Beccia DJ, Elkort RJ, Krane RJ. Adjuvant chemotherapy in renal 
leiomyosarcoma. Urology 1979;13:652-4.
10. Srinivas V, Sogani PC, Hajdu SI, Whitmore WF Jr. Sarcomas of 
the kidney. J Urol 1984;132:13-6.
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et al. Carcinosarcoma arising in mixed epithelial and stromal tu-
mor of the kidney. APMIS 2008;116:1013-5.
12. Kren L, Goncharuk VN, Votava M, Hermanová M, Ross JS, 
Nazeer T, et al. Botryoid-type of embryonal rhabdomyosarcoma 
of renal pelvis in an adult. A case report and review of the litera-
ture. Cesk Patol 2003;39:31-5.
13. Tsai WC, Lee SS, Cheng MF, Lee HS. Botryoid-type pleomorphic 
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14. Lv C, Chen N, Zhu X, Zhang X, Zhong Z. Primary leiomyosarco-
ma of the ureter. Asian J Surg 2008;31:191-4.
15. Parekh DJ, Jung C, O’Conner J, Dutta S, Smith ER Jr. Leiomyosar-
coma in urinary bladder after cyclophosphamide therapy for retino-
blastoma and review of bladder sarcomas. Urology 2002;60: 164.
16. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, 
Tibbs RF, et al. Review of the M.D. Anderson experience in the 
treatment of bladder sarcoma. Urol Oncol 2007;25:38-45.
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presentation and outcome of high-grade urinary bladder leiomyo-
sarcoma in adults. Urology 2003;61:1151-5.
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al. Adult urological sarcoma. J Urol 1992;147:1032-6.
19. Strander H, Turesson I, Cavallin-Ståhl E. A systematic overview 
of radiation therapy effects in soft tissue sarcomas. Acta Oncol 
2003;42:516-31.
20. Sexton WJ, Lance RE, Reyes AO, Pisters PW, Tu SM, Pisters LL. 
Adult prostate sarcoma: the M. D. Anderson Cancer Center Expe-
rience. J Urol 2001;166:521-5.
21. Fisher C, Goldblum JR, Epstein JI, Montgomery E. Leiomyosar-
coma of the paratesticular region: a clinicopathologic study. Am J 
Surg Pathol 2001;25:1143-9.
22. Montgomery E, Fisher C. Paratesticular liposarcoma: a clinico-
pathologic study. Am J Surg Pathol 2003;27:40-7.
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nan MF. A nalysis of the prognostic significance of microscopic 
margins in 2,084 localized primary adult soft tissue sarcomas. Ann 
Surg 2002;235:424-34.
24. Froehner M, Lossnitzer A, Manseck A, Koch R, Noack B, Wirth 
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sarcoma. Urology 2000;56:373-7.
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on univariate analysis. This suggests that physical status of 
patients dictates the recurrence or metastatic potential of 
genitourinary sarcoma. In addition, disease-specific surviv-
al significantly was found to be associated only with FN-
CLCC grade in our series. Tumor grade is a well estab-
lished adverse prognostic factor for soft tissue sarcoma. 
Froehner, et al.24 reported that all 12 patients with low-grade 
genitourinary sarcomas survived; this was true even if the 
tumor was of a giant size, it ruptured spontaneously, there 
was a need for surgical reintervention, there was local re-
currence, or there were metastases. Since a recent study indi-
cated that patients with grade 3 FNCLCC soft tissue sarcoma 
may benefit from anthracycline-based adjuvant chemothera-
py,25 further studies on this issue, including cases of genito-
urinary sarcoma, are needed. 
In conclusion, although adult genitourinary sarcomas are 
a rare group of tumors with a poor prognosis, some patients 
with localized resectable tumors may have a favorable prog-
nosis. Our findings suggest that FNCLCC grade is the most 
important prognostic factor for adult patients with localized 
resectable genitourinary sarcoma. 
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